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INTRODUCTION
Rifampicin is one of the key drugs that have helped toshorten the treatment duration in tuberculosis.
Serious adverse reactions due to rifampicin are
uncommon. Minor side effects like nausea and vomiting
can be managed with symptomatic treatment. Rarely
major adverse reactions endangering life such as
thrombocytopenia1 and acute renal failure2-4 may
develop. Acute renal failure due to rifampicin therapy
though uncommon has been described since 1971.5 It is
usually reversible if detected early and treated
appropriately.
The Tuberculosis Research Centre (TRC) of the Indian
Council of Medical Research has conducted more than
30 controlled clinical trials for the treatment of
pulmonary and extrapulmonary tuberculosis since 1956.
From early 1970’s the TRC has been studying rifampicin-
containing regimens for treating tuberculosis.6 More than
8000 patients with pulmonary or extra- pulmonary
tuberculosis have been treated with rifampicin
containing regimens (daily rifampicin regimens -2000,7,8
daily followed by intermittent rifampicin regimens -810
8,9 and fully intermittent rifampicin - 5500 6). Among these
patients we are reporting three cases of acute renal
failure, probably rifampicin-induced.
CASE REPORTS
Case I
A 25-year-old male weighing 39 kg presented in
February 1997 with fever and cough for one month. He
was normotensive and had crepitations in his right lung.
Chest X-ray showed infiltration of the right upper and
mid-zones. Four sputum smears were positive for
tubercle bacilli by fluorescent microscopy, confirmed
later by positive cultures. Hepatic and renal functions
were normal.
The patient was treated with a daily rifampicin-
containing regimen. Dosage of rifampicin was initially
450 mg and later increased to 600 mg because the patient
gained weight. Though his compliance was not
satisfactory, he responded well to treatment and had
negative sputum smears and cultures at the end of
treatment.
Five months after completing treatment he relapsed
and anti-tuberculosis treatment was restarted with
thrice-weekly isoniazid 600 mg, rifampicin 450 mg,
ethambutol 1200 mg and pyrazinamide 1500 mg. After
20 days he complained of vomiting, anorexia, fever and
oliguria. Blood urea was 173 mg/dl and serum creatinine
17.3 mg/dl. Ultrasound scan of the abdomen showed
normal kidneys with increased cortical echoes.
A diagnosis of rifampicin-induced acute renal failure
was made. He was treated with 3 sessions of peritoneal
dialysis along with salt, protein and fluid restrictions
with close monitoring of fluid intake and output. The
patient refused to consent for renal biopsy. Renal function
improved and in three weeks the blood urea was 45 mg/
dl and serum creatinine 1.2 mg/dl. He was discharged
from the hospital after another week with blood urea of
43 mg/dl and serum creatinine of 1mg/dl. The patient
was successfully treated for tuberculosis with isoniazid
300 mg, ethambutol 800 mg, pyrazinamide 1000 mg daily
from March 1998 for 12 months.
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Case II
A 14-year-old male weighing 42 kg was investigated
for seizures, fever and vomiting in July 1987.
Computerised Tomographic (CT) scan of the brain
revealed a left parieto-temporal lesion suggestive of
tuberculoma with gross edema. He was treated with 3
months of isoniazid 300 mg, rifampicin 450 mg,
pyrazinamide 1000 mg daily followed by 6 months of
isoniazid 600 mg and rifampicin 450 mg twice-weekly
along with anticonvulsants (Eptoin, mazetol). He
successfully completed treatment in April 1988 and the
CT scan at the end of treatment showed a decrease in the
size of the hyperdense lesion with no edema. A CT scan
at the end of the 48th month was normal.
In October 1999, the patient presented with dry cough,
fever, loss of weight and appetite of 3 weeks duration.
Chest x-ray revealed parenchymal lesion of the upper
zone of the left lung. Three sputum smears were positive
for acid-fast bacilli and subsequently the cultures became
positive. He was started on thrice-weekly treatment with
isoniazid 600 mg, rifampicin 600 mg, ethambutol 1200
mg and pyrazinamide 1500 mg.
After 10 days the patient developed low back pain,
anorexia and vomiting. He had renal angle tenderness.
Blood urea was 77 mg/dl and serum creatinine 3.8 mg/
dl. Renal biopsy showed diffuse mesangial proliferation
with patchy interstitial inflammation. The glomeruli
showed mild increase in mesangeal cellularity. The
basement membrane was not thickened. Tubules
appeared unremarkable. The interstitium showed focal
round cell infiltrates and blood vessels were mildly
thickened. Acute renal failure was diagnosed and
rifampicin was stopped; anti-TB treatment was
continued with isoniazid 150 mg, ethambutol 800 mg
and pyrazinamide 750 mg daily on the advice of the
nephrologist.  The renal failure was managed with
peritoneal dialysis along with fluids, salt and protein
restriction. Renal functions returned to normal after five
days with blood urea of 25 mg/dl and serum creatinine
of 1mg/dl. The patient successfully completed anti-
tuberculosis treatment with isoniazid 300 mg,
ethambutol 800 mg, pyrazinamide 1500 mg followed by
isoniazid 300 mg and ethambutol 800 mg daily for 13
months. He responded well to treatment with negative
sputum smears and cultures.
Case III
A 25-year-old male weighing 46 kg presented in May
1996 with cough and fever for one month. He had taken
irregular treatment for pulmonary tuberculosis
elsewhere with a rifampicin-containing daily regimen
for 5 months about a year before. He had crepitations
and rhonchi in both lungs. Chest X-ray showed
infiltration left mid-zone and right lower zone. Two
sputum smears were positive for tubercle bacilli and
subsequently the cultures became positive.
He was started on thrice-weekly isoniazid 600 mg,
rifampicin 450 mg, ethambutol 1200 mg and
pyrazinamide 1500 mg. After 10 days he complained of
oliguria, facial puffiness, pedal edema and vomiting for
4 days. His blood urea was 168 mg/dl and serum
creatinine level 12.8 mg/dl. He refused consent for renal
biopsy. A diagnosis of acute renal failure was made and
rifampicin was stopped. With peritoneal dialysis and
supportive measures renal function became normal in a
month with blood urea level of 39 mg/dl and serum
creatinine of 1 mg/dl. Anti-tuberculosis treatment was
continued with isoniazid 600 mg, ethambutol 600 mg
and pyrazinamide 1500 mg daily. The patient
subsequently developed resistance to streptomycin and
isoniazid and he is now being treated with kanamycin
1g, amoxycillin + clavulanic acid 625 mg, ethambutol
800 mg, clofazamine 100mg and pyrazinamide 1500mg.
He continues to be sputum positive.
DISCUSSION
Rifampicin-induced acute renal failure is sometimes
encountered in the treatment of tuberculosis. More than
100 cases have been reported in the literature and a recent
review from Chennai reported a series of 25 cases.2
All three patients reported here had been previously
treated with daily rifampicin-containing regimens. They
developed acute renal failure following re-treatment
with an intermittent rifampicin regimen. The initiation
of an intermittent rifampicin-containing regimen after
an interval ranging from 5 months to 11 years, led to
acute renal failure, which manifested within 10-20 days
of starting re-treatment.  Although we did not measure
rifampicin dependent antibody levels in these patients
the sequence of events was highly suggestive of
rifampicin-induced acute renal failure. On withholding
rifampicin and providing dialysis and supportive care
the renal insufficiency reversed to normal.
It has been observed that serious adverse reactions to
rifampicin, though rare, manifest more commonly in
patients who are taking rifampicin intermittently or
resume the drug after an interval.10 The cause of such
reactions is postulated to be due to rifampicin-
dependent antibodies.5 The mechanism postulated for
the development of immune induced rifampincin toxicity
is that sufficient quantity of antibodies accumulate
during antigen-free interval when there is a gap in
treatment or during intermittent dose regimen, and when
rifampicin is readministered an intense immune reaction
takes place.10 The immune complexes get deposited in
the blood vessels or interstitium and cause glomerular
endotheliosis leading to tubular injury thereby
decreasing renal function.2 This may possibly be the
cause of renal failure in all three of our patients. The I
antigen expressed on tubular epithelium through which
immune complexes lead to tubular cell destruction was
demonstrated by De Vriese et al.3
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The histological feature of the biopsy in our patient
was suggestive of immune complex deposition in the
interstitium and blood vessels and is consistent with
the predominant pattern observed by Muthukumar et
al2 in renal biopsy of 12 patients with rifampicin-
induced acute renal failure. Fynn  et al4 reported a similar
picture of interstitial edema in the renal biopsy of an
oliguric patient after intermittent rifampicin therapy.
According to De Vriese et al acute tubular necrosis is the
predominant pattern in renal biopsies during acute renal
failure attributed to intermittent rifampicin therapy.3
Chan et al11 explained that immune complex deposition
with compliment fixation leads to glomerular endothelial
swelling which causes obstruction to the blood flow
causing tubular ischemia.
Rifampicin therapy is a milestone in the treatment of
pulmonary tuberculosis and is usually extremely safe.
At TRC we have treated more than 8500 pulmonary and
extrapulmonary tuberculosis patients with rifampicin-
containing regimens in clinical trials. The regimens
included daily and intermittent dosing. All patients were
closely monitored for adverse drug events as part of the
clinical trials protocols. We have not had a single case of
renal failure in these patients during primary treatment.
However during re-treatment with an intermittent
rifampicin-containing regimen in 3 patients who had
been previously treated with a daily rifampicin regimen
we encountered acute renal failure. Our experience
reinforces the fact of the extreme renal safety of this
important drug, but still the physician must be aware of
this rare life-threatening complication, which if detected
early is completely reversible.
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Announcement
Echo and Color Doppler Centre, Sunder Lal Jain Hospital Complex, Ashok Vihar, Phase III, Delhi is
again organizing the XIIth Comprehensive Course on Echocardiography from 2nd Oct. to 7th Oct. 2005.
The course is absolutely based on American and European standards with emphasis on "Hand's on
Training programme" The Course is accredited by IMA Academy of Medical Specialities, Indian Academy
of Echocardiography and Delhi Medical Council.
A limited number of participants with Hands on Training programme shall be enrolled as in previous
courses. An accredited certificate shall be issued to each participant.
For further details contact : Dr. Rakesh Gupta, Organising Secretary Cum Course Director, Echo and Color
Doppler Centre, Sunder Lal Jain Hospital, Ashok Vihar-III, Delhi - 110052.
Tele-Fax : 011-2741-5646, Tele : 011-2713-4839, 98501-70908
Mobile : 98110-3246 (Hutch-1-Echo); E-mail : Jrop2001@yahoo.com
